MX2024005207A - Moduladores de akt3. - Google Patents
Moduladores de akt3.Info
- Publication number
- MX2024005207A MX2024005207A MX2024005207A MX2024005207A MX2024005207A MX 2024005207 A MX2024005207 A MX 2024005207A MX 2024005207 A MX2024005207 A MX 2024005207A MX 2024005207 A MX2024005207 A MX 2024005207A MX 2024005207 A MX2024005207 A MX 2024005207A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- akt3
- modulators
- compositions
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276073P | 2021-11-05 | 2021-11-05 | |
| PCT/US2022/079290 WO2023081812A2 (en) | 2021-11-05 | 2022-11-04 | Akt3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005207A true MX2024005207A (es) | 2024-07-24 |
Family
ID=86242221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005207A MX2024005207A (es) | 2021-11-05 | 2022-11-04 | Moduladores de akt3. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250074905A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4426706A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024541975A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240116621A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118488956A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022381198A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3236906A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL312439A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024005207A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023081812A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021212111A1 (en) * | 2020-04-17 | 2021-10-21 | Augusta University Research Institute, Inc. | Compositions and methods for treating leukemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US7534423B2 (en) | 2003-03-28 | 2009-05-19 | Faron Pharmaceuticals Oy | Method for inducing an elevated level of adenosine in an individual |
| WO2006135627A2 (en) * | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| CA2678180A1 (en) | 2007-02-13 | 2008-12-04 | Northeastern University | Methods and compositions for improving immune responses |
| US11291719B2 (en) * | 2016-01-15 | 2022-04-05 | Augusta University Research Institute, Inc. | Methods and compositions for modulating Akt3 |
| US20230295114A1 (en) * | 2020-05-08 | 2023-09-21 | Georgiamune Llc | Akt3 modulators |
-
2022
- 2022-11-04 IL IL312439A patent/IL312439A/en unknown
- 2022-11-04 KR KR1020247018640A patent/KR20240116621A/ko active Pending
- 2022-11-04 JP JP2024525308A patent/JP2024541975A/ja active Pending
- 2022-11-04 AU AU2022381198A patent/AU2022381198A1/en active Pending
- 2022-11-04 CA CA3236906A patent/CA3236906A1/en active Pending
- 2022-11-04 US US18/707,078 patent/US20250074905A1/en active Pending
- 2022-11-04 WO PCT/US2022/079290 patent/WO2023081812A2/en not_active Ceased
- 2022-11-04 EP EP22891084.0A patent/EP4426706A4/en active Pending
- 2022-11-04 MX MX2024005207A patent/MX2024005207A/es unknown
- 2022-11-04 CN CN202280087271.8A patent/CN118488956A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4426706A2 (en) | 2024-09-11 |
| IL312439A (en) | 2024-06-01 |
| KR20240116621A (ko) | 2024-07-29 |
| CA3236906A1 (en) | 2023-05-11 |
| WO2023081812A2 (en) | 2023-05-11 |
| AU2022381198A1 (en) | 2024-06-20 |
| US20250074905A1 (en) | 2025-03-06 |
| JP2024541975A (ja) | 2024-11-13 |
| EP4426706A4 (en) | 2025-10-15 |
| WO2023081812A3 (en) | 2023-08-31 |
| CN118488956A (zh) | 2024-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020106647A3 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PH12022551379A1 (en) | Substituted tetrahydrofurans as modulators of sodium channels | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| MY208662A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| CR20200520A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2020012679A (es) | Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| EA200970913A1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
| CR20240144A (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| PH12022553031A1 (en) | Akt3 modulators | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| GEAP202115056A (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| MX2024005267A (es) | Moduladores de akt3. | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| MX2022014022A (es) | Moduladores de akt3. | |
| MX2022014021A (es) | Moduladores de akt3. | |
| MX2023005371A (es) | Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso. | |
| MX2024005276A (es) | Moduladores de akt3. | |
| UA106200C2 (uk) | Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину |